Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation (NASDAQ: AMRN) has scheduled its first quarter 2025 financial results announcement and conference call for May 7, 2025. The company will release its Q1 2025 results before market opening, followed by a conference call at 8:00 a.m. ET.
The call will feature Aaron Berg, President & CEO, along with senior management team members, who will discuss the quarterly results and conduct a Q&A session.
- U.S. Dial-in: 888-506-0062
- International Dial-in: 973-528-0011
- Access Code: 253130
For those unable to attend live, a replay will be available through:
- U.S. Replay: 877-481-4010
- International Replay: 919-882-2331
- Replay Access Code: 52230
Investors can also access the live call through the investor relations section at www.amarincorp.com, where a replay will be posted after the event.
Amarin (NASDAQ: AMRN) has announced a 1-for-20 ADS ratio change effective April 11, 2025. This strategic move will adjust the ratio from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.
The primary objective is to increase the per-share market price of Amarin's ADSs to meet Nasdaq's minimum bid price requirement of $1.00 and maintain the company's listing on The Nasdaq Capital Market. The company notes that there is no guarantee that the post-change trading price will be exactly twenty times the pre-change price.
The ratio change will not affect Amarin's ordinary shares, and the ADSs will continue trading under the symbol 'AMRN' on The Nasdaq Capital Market.
Amarin (NASDAQ: AMRN) has announced the immediate appointment of Michael Torok to its Board of Directors. Torok, who is the Co-Founder and Managing Director of investment firm JEC Capital Partners, brings financial expertise and board experience to the position.
Board Chairman Odysseas Kostas, MD, welcomed Torok, highlighting his financial background and alignment with shareholder interests. Torok expressed enthusiasm about working with fellow directors and senior management to maximize shareholder value, emphasizing the board's commitment to transparency.
Amarin (NASDAQ:AMRN) presented key data at ACC.25 demonstrating the mechanistic effects of eicosapentaenoic acid (EPA) and VASCEPA®/VAZKEPA®. The research showed that EPA effectively inhibited oxidation in lipoproteins, particularly in Lp(a)-enriched plasma, which is associated with increased cardiovascular risk.
The studies also revealed positive results when combining EPA with GLP-1 receptor agonist liraglutide, showing enhanced expression of detoxification proteins in endothelial cells during inflammation. Additionally, a recent REDUCE-IT analysis published in JAHA demonstrated that VASCEPA/VAZKEPA provided cardiovascular risk reduction benefits in patients with well-controlled LDL-C levels (<55 mg/dL), highlighting its value as a complementary therapy to standard statin treatment.
A Concerned Shareholder Group, owning approximately 15 million shares of Amarin (NASDAQ: AMRN), has issued an open letter urging the company's Board to initiate an immediate strategic review. The shareholders express disappointment with the company's performance, noting that AMRN's share price has dropped nearly 80% to $0.43 since the Board's reconstitution in February 2023, when it traded at $2.03.
Despite announcing a $50 million share repurchase plan in early 2024 when shares were at $1.15, the company has not executed the buyback. Instead, Amarin recently announced a 1-for-20 reverse stock split. The shareholders highlight that Amarin's market capitalization is approximately $185 million, despite having zero debt and nearly $300 million in cash (~$0.75/share).
Amarin (NASDAQ:AMRN) has announced new in vitro mechanistic research data on eicosapentaenoic acid (EPA) to be presented at the American College of Cardiology's Annual Scientific Session & Expo (March 29-31, 2025, Chicago).
The research focuses on two key areas: the antioxidant effects of EPA on lipoprotein(a) [Lp(a)]-enriched plasma and the combined effects of EPA with GLP-1 receptor agonists on antioxidant protein expression in endothelial cells during inflammation.
Two moderated poster presentations will be available on March 29th, 2025: one at 11:30am ET examining EPA's role in limiting Lp(a)-enriched plasma oxidation, and another at 11:42am ET investigating how EPA enhances detoxification protein expression when combined with GLP-1 agonists in endothelial cells.
Amarin (NASDAQ: AMRN) has announced plans to implement a 1-for-20 ratio change in its American Depositary Shares (ADS) program, expected to take effect around April 11, 2025. The adjustment will modify the current 1:1 ratio between ADS and ordinary shares to 1:20.
This strategic move aims to boost the per-share market price of Amarin's ADSs to meet Nasdaq's minimum bid requirement of $1.00 and maintain its listing on The Nasdaq Capital Market. The company's ordinary shares will remain unaffected, and the ADSs will continue trading under the symbol 'AMRN'.
Holders of uncertificated ADSs will experience automatic conversion, while those with certificated ADSs must surrender them for cancellation to receive new ones. Fractional ADSs will be sold, with net proceeds distributed to affected holders.
Amarin (NASDAQ: AMRN) reported Q4 2024 financial results with total revenues of $62.3 million, down 17% from $74.7 million in Q4 2023. The company ended 2024 with a cash position of $294.2 million and no debt.
Q4 net product revenue was $60.1 million, with U.S. revenue at $44.2 million, European revenue at $4.0 million, and Rest of World revenue at $11.9 million. The company reported a Q4 net loss of $48.6 million, or $0.12 per share.
Amarin announced a 1-for-20 ADS ratio change, expected to be effective April 11, 2025, to maintain Nasdaq listing compliance. The company expanded VASCEPA/VAZKEPA access to six additional global markets including Italy, China, and Australia, with progress in 16 more countries.
Amarin (NASDAQ:AMRN) announced significant findings from a post-hoc analysis of the REDUCE-IT study, published in the Journal of the American Heart Association. The analysis revealed that VASCEPA®/VAZKEPA® (icosapent ethyl) reduced cardiovascular events regardless of baseline LDL-C levels in statin-treated patients with elevated triglycerides and high cardiovascular risk.
Most notably, the study showed a 34% reduction in the primary composite endpoint of cardiovascular events among patients with very well-controlled LDL-C (<55mg/dL). These findings demonstrate that VASCEPA can serve as an effective complementary therapy alongside LDL-C lowering treatments to improve cardiovascular outcomes.
The results align with recent guidelines from the European Society of Cardiology and American Association of Clinical Endocrinology, which recommend LDL-C levels below 55 mg/dL for very high-risk patients and advocate for additional evidence-based therapies beyond standard care.
Amarin plc (NASDAQ:AMRN) has announced that Austria's Health Authorities have approved VAZKEPA® (icosapent ethyl) for national reimbursement, effective April 1, 2025. This approval marks the 10th European national reimbursement for VAZKEPA®, supporting Amarin's continued growth across the continent.
VAZKEPA® will be included in Austria's Code of Reimbursement (EKO) to reduce cardiovascular event risks in adult statin-treated patients with elevated triglycerides and established cardiovascular disease. This comes as cardiovascular diseases represent nearly 35% of all deaths in Austria, with over 100,000 hospitalizations in 2023 and estimated costs of around 4.7 billion euros in 2015.
Professor Christian Hengstenberg from Vienna's University Hospital AKH Wien highlighted that this innovative therapy addresses unmet needs for cardiovascular patients while reducing pressure on healthcare infrastructure. Amarin's CEO Aaron Berg noted that this approval follows Italy's recent national reimbursement and reflects the value recognition based on the REDUCE-IT study data. The company recently secured patent protection extending VAZKEPA's European exclusivity to 2039.